Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

Adoptive cellular therapy using chimeric antigen receptor T-cell (CART) therapy is currently being evaluated in patients with relapsed / refractory multiple myeloma (MM). The majority of CAR-T cell programs now being tested in clinical trials are targeting B-cell maturation antigen. Several recent p...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Philippe Moreau, Pieter Sonneveld, Mario Boccadoro, Gordon Cook, Ma Victoria Mateos, Hareth Nahi, Hartmut Goldschmidt, Meletios A. Dimopoulos, Paulo Lucio, Joan Bladé, Michel Delforge, Roman Hajek, Heinz Ludwig, Thierry Facon, Jesus F. San Miguel, Hermann Einsele
Format:	Artigo
Jezik:	Inglês
Izdano:	Ferrata Storti Foundation 2019-12-01
Serija:	Haematologica
Online dostop:	https://haematologica.org/article/view/9159
Oznake:	Označite Brez oznak, prvi označite!